The entirety of human leukocyte antigen (HLA)‐presented peptides is referred to as the HLA
ligandome of a cell or tissue, in tumours often termed immunopeptidome. Mapping the …

Identification of tumor antigens presented by the human leucocyte antigen (HLA) molecules
is essential for the design of effective and safe cancer immunotherapies that rely on T cell …

The presentation of peptides on class I human leukocyte antigen (HLA-I) molecules plays a
central role in immune recognition of infected or malignant cells. In cancer, non-self HLA-I …

Abstract Knowledge about the peptide repertoire presented by human leukocyte antigens
(HLA) holds the key to unlock target-specific cancer immunotherapies such as adoptive cell …

Presentation of tumor-specific or tumor-associated peptides by HLA class I molecules to
CD8+ T cells is the foundation of epitope-centric cancer immunotherapies. While often in …

Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and
control tumor growth. However, it remains difficult to predict the antigens that will be …

Immunotherapy is revolutionizing cancer treatment and has shown success in particular for
tumors with a high mutational load. These effects have been linked to neoantigens derived …

A challenge in developing personalized cancer immunotherapies is the prediction of
putative cancer‐specific antigens. Currently, predictive algorithms are used to infer binding …

Comprehensive and in-depth identification of the human leukocyte antigen class I (HLA-I)
and class II (HLA-II) tumor immunopeptidome can inform the development of cancer …

One of the challenges for cancer vaccine and adoptive T-cell-based immunotherapy is to
identify the major histocompatibility complex (MHC)-associated non-self neoantigens …